| Methods | D: crossover C: unclear B: double WD: 3/36 J: 1‐2‐1 DU: 4w/2x3m (no washout)/1m (placebo) | |
| Participants | N: 36/33 D: 6 migraine with, 30 without aura C: World Federation of Neurology Research Group F: 89% A: 18‐51 years DU: mean 16 years S: unclear | |
| Interventions | P: 160 mg C: Metoprolol 200 mg | |
| Outcomes | R: 15/33 vs. 17/33 (at least 50% severity score reduction) F: 3.0 (sd 1.9) vs. 3.0 (1.8) AU: 4.7 vs. 4.7 HI: 5.4 vs. 4.9 AEs: similar in both groups Dropouts‐AEs: 2/36 vs. 0/36 V: 0 | |
| Notes | Well‐reported crossover study with low dropout rate | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.